Clinical Trials

Inclusion Criteria

• Age 18-80 years
• Barrett's esophagus with a visible abnormality confirmed upon prior endoscopy
  • A visible abnormality is described as meeting one or more of the following definitions
    • Lesion is detected as visible based on white light imaging with any macroscopic appearance according to the Paris Classification and is also endoscopically resectable
    • Lesion is detected by narrow band imaging (NBI), but without any other specific characteristics for a visible lesion
    • Lesion is confirmed to contain high grade dysplasia and/or carcinoma upon prior biopsy
• Scheduled for endoscopic resection of present neoplasia
• Amenable to Endoscopic Mucosal Resection with no suspicion of submucosal invasion, based on the macroscopic appearance and/or endosonography upon earlier endoscopy
• Taking a proton pump inhibitor twice daily 40 mg or equivalent dosage
• Willing to participate, fully understands the content of the informed consent form, and signs the informed consent form

Exclusion Criteria

• Has previously undergone endoscopic therapy for esophageal neoplasia, including (but not limited to)
  • Cryospray therapy
  • Laser treatment
  • Photodynamic therapy
  • Endoscopic mucosal resection
  • Radiofrequency ablation
  • Argon plasma coagulation
  • Radiotherapy
• Presence of esophageal stenosis preventing passage of a therapeutic gastroscope
• Endoscopically visible scarring by any cause of the intended treatment zone
• Esophageal varices
• Has known or suspected esophageal perforation
• Coagulation disorders or anti-coagulant therapy which cannot be discontinued (aspirin allowed)